Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Increases SIRT-1 activity as a result of enhanced NAD+ salvage, leading to beneficial epigenetic and metabolic reprogramming, including increased oxidative phosphorylation (OXPHOS) and muscle stem cell activation 1-3
Body measurements including waist, hips, thighs, and arms at consistent points provide direct feedback on composition changes
The pivotal trial supporting its 2010 FDA approval enrolled 816 HIV-infected adults with clinically defined lipodystrophy, and Phase 3 data documented visceral fat reductions of roughly 15-18% over 26 weeks of treatment a result robust enough to clear FDA review for a defined medical indication
GHK-Cu has demonstrated potent anti-inflammatory and antioxidant effects: it neutralizes free radicals, reduces oxidative damage, and may lower the risk of follicle-disrupting infections [1]
No UK Marketing Authorisation Identified No current UK marketing authorisation for a medicinal product containing 5-amino-1-methylquinolinium was identified in the official sources reviewed for this article
US$ 26.33
US$ 22.37
US$ 26.17
US$ 20.14
US$ 24.49
